CN103191309B - 脉络宁颗粒剂和制法 - Google Patents
脉络宁颗粒剂和制法 Download PDFInfo
- Publication number
- CN103191309B CN103191309B CN201310116344.4A CN201310116344A CN103191309B CN 103191309 B CN103191309 B CN 103191309B CN 201310116344 A CN201310116344 A CN 201310116344A CN 103191309 B CN103191309 B CN 103191309B
- Authority
- CN
- China
- Prior art keywords
- mailuoning
- granule
- extract
- gained
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 219
- 239000009064 mailuoning Substances 0.000 title claims abstract description 218
- 238000002360 preparation method Methods 0.000 title abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 145
- 150000004676 glycans Chemical class 0.000 claims abstract description 39
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 39
- 239000005017 polysaccharide Substances 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 228
- 238000000034 method Methods 0.000 claims description 118
- 239000012567 medical material Substances 0.000 claims description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 239000006228 supernatant Substances 0.000 claims description 48
- 241000628997 Flos Species 0.000 claims description 43
- 239000004375 Dextrin Substances 0.000 claims description 37
- 229920001353 Dextrin Polymers 0.000 claims description 37
- 235000019425 dextrin Nutrition 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 30
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 26
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 26
- 239000007779 soft material Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 239000012467 final product Substances 0.000 claims description 17
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 16
- 238000012856 packing Methods 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 7
- 206010043540 Thromboangiitis obliterans Diseases 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 5
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 206010019468 Hemiplegia Diseases 0.000 abstract description 4
- 206010022562 Intermittent claudication Diseases 0.000 abstract description 4
- 208000032912 Local swelling Diseases 0.000 abstract description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract description 4
- 206010047249 Venous thrombosis Diseases 0.000 abstract description 4
- 210000003414 extremity Anatomy 0.000 abstract description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract description 4
- 210000003141 lower extremity Anatomy 0.000 abstract description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 206010006784 Burning sensation Diseases 0.000 abstract 1
- 241001523681 Dendrobium Species 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- 239000002245 particle Substances 0.000 description 29
- 239000003814 drug Substances 0.000 description 28
- 239000000463 material Substances 0.000 description 27
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 26
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 25
- 235000013985 cinnamic acid Nutrition 0.000 description 25
- 229930016911 cinnamic acid Natural products 0.000 description 25
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 24
- 239000006260 foam Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000013558 reference substance Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 11
- 238000002791 soaking Methods 0.000 description 11
- 229940013618 stevioside Drugs 0.000 description 11
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 11
- 235000019202 steviosides Nutrition 0.000 description 11
- 238000000605 extraction Methods 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 8
- 239000000080 wetting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000033386 Buerger disease Diseases 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000012850 discrimination method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 3
- 206010013952 Dysphonia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000010985 leather Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- PXMQJPDWGONKAV-YDVPRNJYSA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O PXMQJPDWGONKAV-YDVPRNJYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- JXQGGZBUGUHLEJ-UHFFFAOYSA-N butyl acetate formic acid hydrate Chemical compound O.OC=O.CCCCOC(C)=O JXQGGZBUGUHLEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
编号 | E11* | E12 | E13 | E14 | E15 | E16 | E17 | E18 | E19* |
糊精(份) | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
蔗糖(份) | 1 | 1 | 2 | 3 | 5 | 6 | 7 | 8 | 0 |
编号 | E21 | E22 | E23 | E24 | E25 | E26 | E27 | E28 |
SDS(%) | 0 | 0.02 | 0.05 | 0.1 | 0.25 | 0.5 | 0.75 | 1.2 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310116344.4A CN103191309B (zh) | 2013-02-19 | 2013-04-03 | 脉络宁颗粒剂和制法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310061242 | 2013-02-19 | ||
CN201310061242.7 | 2013-02-19 | ||
CN201310116344.4A CN103191309B (zh) | 2013-02-19 | 2013-04-03 | 脉络宁颗粒剂和制法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103191309A CN103191309A (zh) | 2013-07-10 |
CN103191309B true CN103191309B (zh) | 2014-10-29 |
Family
ID=48714243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310116344.4A Active CN103191309B (zh) | 2013-02-19 | 2013-04-03 | 脉络宁颗粒剂和制法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103191309B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104857390A (zh) * | 2015-05-30 | 2015-08-26 | 青岛辰达生物科技有限公司 | 一种治疗间歇性跛行的中药组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435250A (zh) * | 2003-03-12 | 2003-08-13 | 李雁青 | 注射用脉络宁口服固体制剂的制备方法 |
CN1857617A (zh) * | 2006-03-14 | 2006-11-08 | 石家庄制药集团欧意药业有限公司 | 无糖型脉络宁颗粒及其制备方法与质量控制方法 |
CN101480470A (zh) * | 2008-01-09 | 2009-07-15 | 北京卓越同创药物研究院 | 脉络宁制剂在治疗风湿类疾病中的应用 |
-
2013
- 2013-04-03 CN CN201310116344.4A patent/CN103191309B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435250A (zh) * | 2003-03-12 | 2003-08-13 | 李雁青 | 注射用脉络宁口服固体制剂的制备方法 |
CN1857617A (zh) * | 2006-03-14 | 2006-11-08 | 石家庄制药集团欧意药业有限公司 | 无糖型脉络宁颗粒及其制备方法与质量控制方法 |
CN101480470A (zh) * | 2008-01-09 | 2009-07-15 | 北京卓越同创药物研究院 | 脉络宁制剂在治疗风湿类疾病中的应用 |
Non-Patent Citations (1)
Title |
---|
方霞等.中药颗粒剂.《中药药剂学》.科学出版社,2004,第127页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103191309A (zh) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102600219B (zh) | 黄蜀葵花总黄酮提取物及其制备方法 | |
CN103610757B (zh) | 用于清热化痰解毒的注射液 | |
CN102657823A (zh) | 一种具有抗癌作用的中药组合物及其制备方法和检测方法 | |
CN101274025A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和质量控制方法 | |
CN101422563A (zh) | 治疗小儿咽喉炎的中药组合物及其制备方法和质量控制方法 | |
CN103823034A (zh) | 一种金银花对照提取物及其制备方法 | |
CN102228506A (zh) | 补骨脂提取物的组合物及其制备方法和用途 | |
CN104644578A (zh) | 磷酸西格列汀组合物片剂及其制备方法 | |
CN102397342A (zh) | 一种金荞麦提取物,含其制剂及其制备方法 | |
CN106074422A (zh) | 一种琥珀酸曲格列汀口服固体制剂及其制备方法 | |
CN103191309B (zh) | 脉络宁颗粒剂和制法 | |
CN103585204B (zh) | 一种稳定性好的百蕊颗粒剂及其制备方法 | |
CN102188492B (zh) | 一种复方银翘氨敏胶囊的制备方法 | |
CN101816693B (zh) | 一种紫锥菊提取物散剂及其制备方法和应用 | |
CN103675135B (zh) | 一种中药组合物的含量测定方法 | |
CN1857445B (zh) | 一种得生制剂的检测方法 | |
CN100478015C (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
CN103142474B (zh) | 以高纯度银杏内酯b为活性成分的组合物及其制备方法 | |
CN101933996A (zh) | 一种具有清热泻火解毒作用的中药组合物及其制备方法和检测方法 | |
CN112957344B (zh) | 一种含西番莲黄酮纳米制剂及其制备方法 | |
CN100490783C (zh) | 无糖型脉络宁颗粒及其制备方法与质量控制方法 | |
CN1931272B (zh) | 一种治疗妇科疾病药物胶囊剂的质量检测方法 | |
CN101428020A (zh) | 一种苦参素冻干粉制剂及其制备和检测方法 | |
CN105675751B (zh) | 抗病毒口服液的质量检测方法 | |
CN101274037A (zh) | 治疗皮肤瘙痒病的组合物及其制备方法和质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LI YOUXIANG Free format text: FORMER OWNER: LIU WEI Effective date: 20150722 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150722 Address after: 201203 No. 1399 Zhang Heng Road, Shanghai, Pudong New Area Patentee after: Li Youxiang Address before: 100083 No. 38, Haidian District, Beijing, Xueyuan Road Patentee before: Liu Wei |
|
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Jianrong Inventor after: Li Houru Inventor before: Liu Wei |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150914 Address after: 344100, Jiangxi, Linchuan Fuzhou District Industrial Park only 3 silver Tao Road Patentee after: JIANGXI YINTAO PHARMACEUTICAL CO.,LTD. Address before: 201203 No. 1399 Zhang Heng Road, Shanghai, Pudong New Area Patentee before: Li Youxiang |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mailuoning granule and preparation method Effective date of registration: 20200611 Granted publication date: 20141029 Pledgee: Fuzhou Fuhe sub branch of Agricultural Bank of China Ltd. Pledgor: JIANGXI YINTAO PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003006 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210319 Granted publication date: 20141029 Pledgee: Fuzhou Fuhe sub branch of Agricultural Bank of China Ltd. Pledgor: JIANGXI YINTAO PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003006 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 344100 No.3, Yintao Avenue, caidu Industrial Park, Linchuan District, Fuzhou City, Jiangxi Province Patentee after: Jiangxi Yintao Pharmaceutical Co.,Ltd. Address before: 344100 No.3, Yintao Avenue, caidu Industrial Park, Linchuan District, Fuzhou City, Jiangxi Province Patentee before: JIANGXI YINTAO PHARMACEUTICAL CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |